Sugi Predict

Sugi Predict / Compounds / SCHEMBL1016475

SCHEMBL1016475

SCHEMBL1016475

CC(=O)Nc1ccc(B(O)OC(C)(C)C(C)(C)O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ HTT P42858 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ KMT2A Q03164 5/20 0.44
▸ MEN1 O00255 4/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CA2 P00918 2/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ CA12 O43570 1/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ NR1I2 O75469 1/20 0.43
▸ MB P02144 1/20 0.43
▸ CYP1A1 P04798 1/20 0.43
▸ CA3 P07451 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ RARG P13631 1/20 0.43
▸ TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3348070 0.87 KIF11 (0.45) L3MBTL1KMT2AMEN1ALDH1A1MAPT
SCHEMBL2370528 0.85 TRPV1 (0.46) SMN1; SMN2HTTL3MBTL1KMT2AMEN1
SCHEMBL1991350 0.84 CYP17A1 (0.43) CA1CA9CA12BRD4NAMPT
SCHEMBL1015209 0.83 ALDH1A1 (0.45) SMN1; SMN2L3MBTL1KMT2AMEN1ALDH1A1
SCHEMBL443381 0.82 TRPV1 (0.44) KMT2AMEN1CA1CA2CA9
SCHEMBL2369624 0.81 EPHX1 (0.50) SMN1; SMN2ALDH1A1CYP3A4RAB9ACYP2C19
SCHEMBL6610808 0.81 CYP17A1 (0.49) CA1CA9CA12BRD4NAMPT
SCHEMBL3519257 0.81 TRPV1 (0.32) ALDH1A1CYP3A4TSHRHPGDTRPV1
SCHEMBL2369397 0.80 KMT2A (0.51) SMN1; SMN2HTTKMT2AMEN1ALDH1A1
SCHEMBL248554 0.79 PTK2 (0.46) SMN1; SMN2L3MBTL1KMT2AMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3186245-B1 MAPK INHIBITORS EverBrilliant Pharma Pty Ltd (AU) 2021-06-23 — — EP disclosed
CN-107074831-B MAPK inhibitors 永辉药业 2020-12-08 — — CN disclosed
US-20180289684-A1 MAPK INHIBITORS EverBrilliant Pharma Pty Ltd (AU) 2018-10-11 — — US disclosed
US-20170266173-A1 MAPK INHIBITORS EVERBRILLIANT PHARMA PTY LTD. (AU) 2017-09-21 — — US disclosed
EP-3186245-A1 MAPK INHIBITORS Wang, Bing Hui (AU) 2017-07-05 — — EP disclosed
WO-2016029263-A1 MAPK INHIBITORS WANG BING HUI (AU) 2016-03-03 — — WO disclosed
US-20150315127-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2015-11-05 — — US disclosed
US-9024071-B2 Therapeutic compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-05-05 — — US disclosed
EP-2318377-B1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH INC (US) 2013-08-21 — — EP disclosed
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 — — US disclosed
US-20120165313-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2012-06-28 — — US disclosed
US-20120149693-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-06-14 — — US disclosed
US-8163763-B2 Pyrimidine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-04-24 — — US disclosed
US-7976959-B2 Organic electroluminescent element including bibenzothiopene containing organic compound and display device including the same FUJI XEROX CO., LTD. (JP) 2011-07-12 — — US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 — — US disclosed
EP-2318377-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Genentech, Inc. (US) 2011-05-11 — — EP disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 — — EP disclosed
US-20100069357-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-03-18 — — US disclosed
WO-2010014939-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-02-04 — — WO disclosed
US-20090243469-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND DISPLAY DEVICE INCLUDING THE SAME FUJI XEROX CO., LTD. (JP) 2009-10-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149693-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 SMN1; SMN2 3273/4885HTT 808/4885L3MBTL1 4393/4885
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 SMN1; SMN2 2290/4885HTT 1349/4885L3MBTL1 2670/4885
US-20170266173-A1 MAPK INHIBITORS MAPK1, MAPK4, MAPK3 SMN1; SMN2 4482/4885HTT 4593/4885L3MBTL1 2687/4885
US-20150315127-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 SMN1; SMN2 3273/4885HTT 808/4885L3MBTL1 4393/4885
US-20120165313-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE MTOR, TYMS, DTYMK SMN1; SMN2 1868/4885HTT 2645/4885L3MBTL1 4281/4885
US-20100069357-A1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE MTOR, TYMS, DTYMK SMN1; SMN2 1868/4885HTT 2645/4885L3MBTL1 4281/4885
US-20180289684-A1 MAPK INHIBITORS MAPK1, MAPK4, MAPK3 SMN1; SMN2 4482/4885HTT 4593/4885L3MBTL1 2687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.